Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 12, 2008 Brian Orelli	Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab.
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool June 11, 2007 Brian Lawler	Overseas Action for SGP Schering gets an expanded label and begins marketing another drug overseas. Investors often overlook the importance that markets outside the U.S. offer for pharmaceutical products.
The Motley Fool July 24, 2007 Brian Orelli	No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note.
The Motley Fool October 4, 2007 Brian Orelli	Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.
BusinessWeek October 2, 2006 Gene G. Marcial	Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play.
BusinessWeek October 10, 2005	J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows.
The Motley Fool October 23, 2006 Brian Lawler	The New Schering-Plough Possibly the cheapest large-cap pharmaceutical company compared with its growth potential, the new Schering-Plough is no dirt. Investors craving only one domestic large-cap pharma stock might be happiest with the new Schering.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool March 11, 2011 Brian Orelli	Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool October 7, 2008 Brian Orelli	Will a Better Drug Sell Better? Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool November 21, 2007 Brian Lawler	Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
The Motley Fool August 14, 2009 Brian Orelli	The Schizophrenic Drug Approval Schering's drug gets a thumbs-up.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool October 17, 2007 Brian Orelli	J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
BusinessWeek December 22, 2003 Robert Barker	A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths.
BusinessWeek April 17, 2006 Amy Barrett	J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock.
The Motley Fool November 27, 2007 Brian Orelli	Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool June 30, 2008 Brian Orelli	Merck and Schering Get Half a Divorce The lovey-dovey duo ends their respiratory partnership.
The Motley Fool February 10, 2004 David Nierengarten	The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool February 13, 2008 Brian Orelli	Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter.
The Motley Fool November 25, 2008 Brian Orelli	Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there.
The Motley Fool July 24, 2007 Brian Lawler	Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters.
The Motley Fool July 13, 2004 Jeff Hwang	J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent.
The Motley Fool April 8, 2005 David Nierengarten	The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects.
BusinessWeek September 30, 2009 Arlene Weintraub	J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D.
The Motley Fool July 23, 2007 Brian Lawler	A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.